WOCKPHARMAWockhardt Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹21,319 Cr
Primary DriverGovernance
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
14 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in governance. This indicates that forensic pressure is currently receding. Risk levels are improving.

35.4th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹1,966.2▼8.67%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Stability Adjustment
+14.0 pts
Final Composite Risk14 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 11 → 14 over 13 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Relative Growth Weakness
  • Working Capital Expansion
What to Watch Next Quarter
  • Operating profit margins
  • Inventory turnover
  • Working capital efficiency

Active Risk Objects (4)

CriticalHigh
Relative Growth Weakness
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ2 FY2026
Revenue growth consistently lags behind sector median (12.8%).

"Earnings quality is under severe pressure. High accruals suggest potential revenue overstatement."

Inventory Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ2 FY2026
Inventory growth (31.8%) significantly outpaced revenue growth (-1.8%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 10 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ3 FY2026
WOCKPHARMA: Low Interest Coverage Ratio of 2.12x in FY2026 Q3 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2025
Working capital expansion detected: Receivable days increased by 6.4%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)1.927.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+52.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,966.2(-8.67%)
1M Divergence+38.62%
1 Week+15.65%
1 Month+40.89%
6 Months+47.62%
1 Year+34.12%
2 Year+271.44%
3 Year+1067.58%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

WOCKPHARMA • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.92%
Trend QualityDeveloping
Phase Progression
Phase Progression Score85%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing92%
CoinTree Momentum
Composite Z-Score+1.9410σ
Strong positive momentum leadership
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#99 of 2716
Top 3.65% in momentum strength
Timeframe Sparklines
1W+15.7%
1M+40.9%
6M+47.6%
Weinstein Indicators
150 DMA₹1,395.51
200 DMA₹1,411.82
150 DMA Slope+2.5415%Rising
Relative Strength+53.11%Leading
Relative Turnover (RTR)2.9807
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
WOCKPHARMAWockhardt Limited
14 Risk
Sector %ile35th
Delta-5
Active Flags4
Accel+0
Governance

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Relative Growth Weakness

2026

Inventory Stress

2026

Relative Growth Weakness

2025

Inventory Stress

2025

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20263,4841993902,125
FY20253,074-57-221,859
FY20242,881-4722192,112
FY20232,773-6211531,887